Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07259213 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC

Name: A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC — clinical trial record (NCT07259213)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: RAD402

StatusRecruiting

PhasePhase 1/2

SponsorRadiopharm Theranostics, Ltd

Started2026-03-05

View on ClinicalTrials.gov ↗

Amendment history

2026-03-30

Study Status, Contacts/Locations v3

Study sites1→2

2026-03-11

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2026-02-20→confirmed 2026-03-05

Study sites0→1

2026-02-08

Study Status v1

Start date2025-11-30→2026-02-20

2025-11-26

Original filing

Radiopharm Theranostics, Ltd

7 trials monitored

See 3 trials at risk

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-KLK3 Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants with Castration-Resistant Prostate Cancer (CRPC).

Trial Details

NCT Number	NCT07259213
Lead Sponsor	Radiopharm Theranostics, Ltd
Conditions	Castration-resistant Prostate Cancer
Enrollment	73 participants
Start Date	2026-03-05
Primary Completion	2028-11-30 (estimated)
Study Completion	2029-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-01